首页|急性B淋巴细胞白血病BCL-2抑制剂耐药细胞系的构建及耐药机制研究

急性B淋巴细胞白血病BCL-2抑制剂耐药细胞系的构建及耐药机制研究

扫码查看
目的:利用急性B淋巴细胞白血病(B-ALL)细胞系RS4;11构建对BCL-2抑制剂耐药的耐药细胞系,并探讨其可能的耐药机制.方法:采用BCL-2抑制剂navitoclax和venetoclax小剂量低浓度递增的方法间歇诱导RS4;11细胞系,构建RS4;11/Nav和RS4;11/Ven耐药细胞系,通过MTT法检测不同药物浓度下细胞的存活率,流式细胞术检测细胞凋亡,转录组测序技术(RNA-seq)检测RS4;11耐药细胞系和亲本细胞系中的差异表达基因(DEGs),RT-PCR检测耐药细胞系与亲本细胞系中差异表达基因的mRNA表达水平,Western blot检测耐药细胞系和亲本细胞系中BCL-2家族抗凋亡蛋白的表达水平.结果:成功构建了对BCL-2抑制剂耐药的耐药细胞系RS4;11/Nav和RS4;11/Ven,RS4;11/Nav 对 navitoclax 的耐药指数为 328.655±47.377,RS4;11/Ven 对 venetoclax 的耐药指数为 2 894.027±300.311.流式细胞术检测细胞凋亡发现,相比耐药细胞系,RS4;11亲本细胞系明显被BCL-2抑制剂抑制,而耐药细胞系的凋亡率基本未受药物的影响.Western blot检测结果表明,BCL-2家族抗凋亡蛋白在耐药细胞系中的表达无明显增多.RNA-seq、RT-PCR和Western blot检测发现EP300在耐药细胞系中的表达较亲本细胞系明显增高(P<0.05).结论:小剂量低浓度递增间歇诱导法可成功构建对BCL-2抑制剂耐药的B-ALL细胞系,并且其耐药机制可能与EP300的表达上调有关.
Establishment of BCL-2 Inhibitors-Resistant B-cell Acute Lymphoblastic Leukemia Cell Lines and Study on Their Resistance Mechanisms
Objective:RS4;11 cell line was used to establish BCL-2 inhibitor-resistant cell lines of B-cell acute lymphoblastic leukemia(B-ALL)and explore the possible mechanisms of drug resistance.Methods:RS4;11 cell line was continuously induced and cultured by low and ascending concentrations of BCL-2 inhibitors navitoclax and venetoclax to construct navitoclax-resistant cell line RS4;11/Nav and venetoclax-resistant cell line RS4;11/Ven.The cell viability was detected by MTT assay,and the cell apoptosis was detected by flow cytometry.Differentially expressed genes(DEGs)between RS4;11 drug-resistant cell lines and parental cell line were detected by transcriptome sequencing technology(RNA-seq),and mRNA expression levels of DEGs between drug-resistant cell lines and parental cell line were detected by real-time PCR(RT-PCR).Western blot was used to detect the expression levels of BCL-2 family anti-apoptotic proteins in drug-resistant cell lines and parental cell line.Results:The drug-resistant cell lines RS4;11/Nav and RS4;11/Ven were successfully established.The resistance index(RI)of RS4;11/Nav to navitoclax and RS4;11/Ven to venetoclax was 328.655±47.377 and 2 894.027±300.311,respectively.The results of cell apoptosis detection showed that compared with the drug-resistant cell lines,RS4;11 parental cell line were significantly inhibited by BCL-2 inhibitors,while the apoptosis rate of drug-resistant cell lines was not affected by the drugs.Western blot assay showed that the expression of anti-apoptotic proteins of BCL-2 family did not increase significantly in drug-resistant cell lines.RNA-seq,RT-PCR and Western blot assays showed that the expression of EP300 in drug-resistant cell lines was significantly higher than that in parental cell line(P<0.05).Conclusion:Drug-resistant B-ALL cell lines could be successfully established by exposing RS4;11 cell line to the ascending concentration of BCL-2 inhibitors,and the drug resistance mechanism may be related to the overexpression of EP300.

B-cell acute lymphoblastic leukemiaBCL-2 inhibitorsdrug-resistant cell lineRNA-seqEP300

吴沂璇、段永娟、蔡玉丽、魏璇、张英驰、章婧嫽、竺晓凡

展开 >

中国医学科学院血液病医院(中国医学科学院血液学研究所),北京协和医学院血液病医院(北京协和医学院血液学研究所),实验血液学国家重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020

天津医学健康研究院,天津 301600

急性B淋巴细胞白血病 BCL-2抑制剂 耐药细胞系 RNA-seq EP300

2024

中国实验血液学杂志
中国病理生理学会

中国实验血液学杂志

CSTPCD北大核心
影响因子:0.988
ISSN:1009-2137
年,卷(期):2024.32(5)